Proliferation and estrogen signaling can distinguish patients at risk for early versus late relapse among estrogen receptor positive breast cancers
about
The shortest path is not the one you know: application of biological network resources in precision oncology researchPAM50 gene signatures and breast cancer prognosis with adjuvant anthracycline- and taxane-based chemotherapy: correlative analysis of C9741 (Alliance).Intrinsic subtypes from the PAM50 gene expression assay in a population-based breast cancer survivor cohort: prognostication of short- and long-term outcomesFibroblast growth factor receptor-1 protein expression is associated with prognosis in estrogen receptor-positive/human epidermal growth factor receptor-2-negative primary breast cancer.Prognostic Impact of the Combination of Recurrence Score and Quantitative Estrogen Receptor Expression (ESR1) on Predicting Late Distant Recurrence Risk in Estrogen Receptor-Positive Breast Cancer After 5 Years of Tamoxifen: Results From NRG OncologDecision-making impact on adjuvant chemotherapy allocation in early node-negative breast cancer with a 21-gene assay: systematic review and meta-analysis.Promoter Methylation Analysis Reveals That KCNA5 Ion Channel Silencing Supports Ewing Sarcoma Cell Proliferation.Body mass index, PAM50 subtype, recurrence, and survival among patients with nonmetastatic breast cancer.TFAP2C expression in breast cancer: correlation with overall survival beyond 10 years of initial diagnosis.An unmet need: tailoring extended adjuvant endocrine therapy.Hypoxia-related biological markers as predictors of epirubicin-based treatment responsiveness and resistance in locally advanced breast cancer.Novel 18-gene signature for predicting relapse in ER-positive, HER2-negative breast cancerFatty acid oxidation is associated with proliferation and prognosis in breast and other cancers
P2860
Q26999241-8AABCBE1-57CB-430A-B7F7-6FE364D4BE53Q33883406-AE93F083-2154-421F-B712-427195EA9492Q33927000-D8CB59C1-2C53-4700-9BFA-7448D8387EA0Q36801189-BE19F98A-1AB0-426B-9EEF-87A2138D05B7Q37169337-6897C505-299F-4BCC-8E8F-6D8776B8D77DQ38540963-81245E38-2D83-4E67-B5E1-9997941C9AB2Q38819288-F8FE4733-BABB-477C-8928-12ACE1E2B722Q40291664-553762DC-1E90-477A-B02D-881D1164F27EQ41598833-C1508B09-F382-432C-B451-9980F8FF03CBQ42813847-10A11B89-2622-4911-9A54-C001968211ACQ44221870-226A02C2-0030-4050-B1AB-47A2028C2637Q56515226-D787835E-0AF8-4B0F-B819-EE5CE0463810Q58793433-CC955967-D955-44F4-8CDC-F2C80AA3405B
P2860
Proliferation and estrogen signaling can distinguish patients at risk for early versus late relapse among estrogen receptor positive breast cancers
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Proliferation and estrogen sig ...... ceptor positive breast cancers
@en
Proliferation and estrogen sig ...... eptor positive breast cancers.
@nl
type
label
Proliferation and estrogen sig ...... ceptor positive breast cancers
@en
Proliferation and estrogen sig ...... eptor positive breast cancers.
@nl
prefLabel
Proliferation and estrogen sig ...... ceptor positive breast cancers
@en
Proliferation and estrogen sig ...... eptor positive breast cancers.
@nl
P2093
P2860
P50
P356
P1476
Proliferation and estrogen sig ...... ceptor positive breast cancers
@en
P2093
Achim Rody
Angelica Fasolo
Catherine Kelly
Christos Sotiriou
Giampaolo Bianchini
Gianluca Del Conte
Lajos Pusztai
Milvia Zambetti
Schmidt Schmidt
Sven Becker
P2860
P2888
P356
10.1186/BCR3481
P577
2013-01-01T00:00:00Z
P5875
P6179
1001304330